A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing

Paris Roach, Yehiel Zick, Pietro Formisano, Domenico Accili, Simeon I. Taylor, Phillip Gorden

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The precise nature of the insulin-binding site of the insulin receptor (IR) has not been determined, although the importance of several regions of the α-subunit in insulin binding has been demonstrated. A naturally occurring mutation in a patient with severe insulin resistance that changes the Ser323 codon in the α-subunit of the IR to a leucine codon is associated with markedly impaired insulin binding to cells from the patient and to transfected cells expressing the mutant receptor. However, unlike other IR α-subunit mutations associated with decreased insulin binding, this mutation does not lead to a defect in posttranslational processing or cell- surface expression of IRs. Thus, the defect in insulin binding associated with the Leu323 mutant IR is a direct result of an alteration in the insulin-binding site. No natural IR mutation described thus far is associated with both decreased insulin binding and normal cell-surface expression of the mutant receptor. This study demonstrates the critical role that Ser323 of the IR α-subunit plays in insulin binding, either by forming part of the binding site or by stabilizing its conformation.

Original languageEnglish (US)
Pages (from-to)1096-1102
Number of pages7
JournalDiabetes
Volume43
Issue number9
StatePublished - 1994
Externally publishedYes

Fingerprint

Insulin Receptor
Insulin
Mutation
Genes
Binding Sites
Codon
human INSR protein
Leucine
Insulin Resistance

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Roach, P., Zick, Y., Formisano, P., Accili, D., Taylor, S. I., & Gorden, P. (1994). A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing. Diabetes, 43(9), 1096-1102.

A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing. / Roach, Paris; Zick, Yehiel; Formisano, Pietro; Accili, Domenico; Taylor, Simeon I.; Gorden, Phillip.

In: Diabetes, Vol. 43, No. 9, 1994, p. 1096-1102.

Research output: Contribution to journalArticle

Roach, P, Zick, Y, Formisano, P, Accili, D, Taylor, SI & Gorden, P 1994, 'A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing', Diabetes, vol. 43, no. 9, pp. 1096-1102.
Roach, Paris ; Zick, Yehiel ; Formisano, Pietro ; Accili, Domenico ; Taylor, Simeon I. ; Gorden, Phillip. / A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing. In: Diabetes. 1994 ; Vol. 43, No. 9. pp. 1096-1102.
@article{07d689086d644520b0a4e1a6b76973da,
title = "A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing",
abstract = "The precise nature of the insulin-binding site of the insulin receptor (IR) has not been determined, although the importance of several regions of the α-subunit in insulin binding has been demonstrated. A naturally occurring mutation in a patient with severe insulin resistance that changes the Ser323 codon in the α-subunit of the IR to a leucine codon is associated with markedly impaired insulin binding to cells from the patient and to transfected cells expressing the mutant receptor. However, unlike other IR α-subunit mutations associated with decreased insulin binding, this mutation does not lead to a defect in posttranslational processing or cell- surface expression of IRs. Thus, the defect in insulin binding associated with the Leu323 mutant IR is a direct result of an alteration in the insulin-binding site. No natural IR mutation described thus far is associated with both decreased insulin binding and normal cell-surface expression of the mutant receptor. This study demonstrates the critical role that Ser323 of the IR α-subunit plays in insulin binding, either by forming part of the binding site or by stabilizing its conformation.",
author = "Paris Roach and Yehiel Zick and Pietro Formisano and Domenico Accili and Taylor, {Simeon I.} and Phillip Gorden",
year = "1994",
language = "English (US)",
volume = "43",
pages = "1096--1102",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing

AU - Roach, Paris

AU - Zick, Yehiel

AU - Formisano, Pietro

AU - Accili, Domenico

AU - Taylor, Simeon I.

AU - Gorden, Phillip

PY - 1994

Y1 - 1994

N2 - The precise nature of the insulin-binding site of the insulin receptor (IR) has not been determined, although the importance of several regions of the α-subunit in insulin binding has been demonstrated. A naturally occurring mutation in a patient with severe insulin resistance that changes the Ser323 codon in the α-subunit of the IR to a leucine codon is associated with markedly impaired insulin binding to cells from the patient and to transfected cells expressing the mutant receptor. However, unlike other IR α-subunit mutations associated with decreased insulin binding, this mutation does not lead to a defect in posttranslational processing or cell- surface expression of IRs. Thus, the defect in insulin binding associated with the Leu323 mutant IR is a direct result of an alteration in the insulin-binding site. No natural IR mutation described thus far is associated with both decreased insulin binding and normal cell-surface expression of the mutant receptor. This study demonstrates the critical role that Ser323 of the IR α-subunit plays in insulin binding, either by forming part of the binding site or by stabilizing its conformation.

AB - The precise nature of the insulin-binding site of the insulin receptor (IR) has not been determined, although the importance of several regions of the α-subunit in insulin binding has been demonstrated. A naturally occurring mutation in a patient with severe insulin resistance that changes the Ser323 codon in the α-subunit of the IR to a leucine codon is associated with markedly impaired insulin binding to cells from the patient and to transfected cells expressing the mutant receptor. However, unlike other IR α-subunit mutations associated with decreased insulin binding, this mutation does not lead to a defect in posttranslational processing or cell- surface expression of IRs. Thus, the defect in insulin binding associated with the Leu323 mutant IR is a direct result of an alteration in the insulin-binding site. No natural IR mutation described thus far is associated with both decreased insulin binding and normal cell-surface expression of the mutant receptor. This study demonstrates the critical role that Ser323 of the IR α-subunit plays in insulin binding, either by forming part of the binding site or by stabilizing its conformation.

UR - http://www.scopus.com/inward/record.url?scp=0028086357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028086357&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 1096

EP - 1102

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -